New Resident Company, EdiGene, Raises 62 Million in Series B Plus Financing
This month, we welcomed staff from EdiGene and have been excited to witness their rapid growth! EdiGene scientists aim to accelerate drug discovery for diseases and cancer by developing their genome editing technologies.
EdiGene just announced that after a successful round of financing, they raised
62 million USD which will contribute to the companies efforts to streamline business operations and promote the company’s pipeline into clinics.
Read more on EdiGene's website here...